Page 7 - T Cell News Today

Approximately 3–5% of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced disease, accounting for roughly 1% of all cancer deaths in Australia. Immunotherapy has demonstrated significant clinical benefit in advanced CSCC in several key phase II studies; however, there are limited data for patients treated outside of clinical trials. This is particularly relevant in advanced CSCC, which is most often seen in elderly patients with significant comorbidities. Thus, we aim to de...

"We are seeing some truly surprising response rates and progression-free survival data," says chairman of Unicancer and general director of the Léon Bérard Center in France.

Review examines nirmatrelvir and bisphosphonates in treating COVID-19, revealing their impact on SARS-CoV-2-specific adaptive immunity and potential to mitigate severe infections, highlighting the need for balanced long-term immunity management.

A lipidic peptide, named IK14004.

Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The

Research explores the advancements, challenges, and economic implications of gene therapy for various diseases, including inherited blood disorders, malignancies treated with CAR-T cells, and diseases targeted by in vivo AAV vectors. The review highlights the transformative potential of gene therapies while acknowledging the complexities in manufacturing, safety, efficacy, and long-term durability.

We sat down with Mark Sundrud, PhD, to discuss bile acids and T cells in cholestatic liver disease and the future of research regarding the interplay between intestinal and liver functions.

The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.

As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.

Severe Combined Immunodeficiencies (SCIDs) are a group of debilitating primary immunodeficiency disorders, primarily caused by genetic mutations that disrupt T-cell development. SCID can also affect B-cell and natural killer cell function and counts.